The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Cyclospasmol     (3,3,5-trimethylcyclohexyl) 2-hydroxy-2...

Synonyms: Cyclolyt, Perebral, Saiclate, Capilan, Clandilon, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of cyclandelate


Psychiatry related information on cyclandelate


High impact information on cyclandelate


Chemical compound and disease context of cyclandelate


Biological context of cyclandelate


Anatomical context of cyclandelate


Associations of cyclandelate with other chemical compounds


Gene context of cyclandelate

  • The inhibition of cholesterol esterification by cyclandelate in transformed mouse macrophages [23].
  • The effects of two acylcoenzyme A: cholesterol acyltransferase (ACAT) inhibitors, cyclandelate and a non-hydrolysable ether analogue, benzyl3,3,5-trimethylcyclohexanol on low density lipoprotein metabolism in macrophages and hepatocytes [24].
  • Cyclandelate bound to beta 2-sites and blocked calcium accumulation [25].
  • Of particular interest is that following cyclandelate treatment the absolute theta power remained almost unchanged and an increase of P300 amplitude was observed [26].
  • An average reduction of about 50% in FA, TPI and AwH was already observed in the cyclandelate group after 4-6 weeks suggesting an early onset of action [27].

Analytical, diagnostic and therapeutic context of cyclandelate


  1. Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine. Nappi, G., Sandrini, G., Savoini, G., Cavallini, A., de Rysky, C., Micieli, G. Drugs (1987) [Pubmed]
  2. Cyclandelate in the treatment of vertigo of circulatory origin. A study in general practice. de Halleux, F. Drugs (1987) [Pubmed]
  3. Perceived efficacy of cyclandelate in the treatment of cochleovestibular and retinal disturbances related to cerebrovascular insufficiency. A study in general practice comprising 2772 patients. Memin, Y. Drugs (1987) [Pubmed]
  4. Cyclandelate as a calcium modulating agent in rat cerebral cortex. Bast, A., Leurs, R., Timmerman, H. Drugs (1987) [Pubmed]
  5. Clinical experience with cyclandelate in insulin-dependent diabetic patients with neuropathy. De Leeuw, I.H., Van Rooy, P., Moeremans, M., Driessens, M. Drugs (1987) [Pubmed]
  6. Effect of cyclandelate on dementia. Westreich, G., Alter, M., Lundgren, S. Stroke (1975) [Pubmed]
  7. Specific effects of cyclandelate on memory. Ananth, J. Drugs (1987) [Pubmed]
  8. Cyclandelate in the treatment of multi-infarct dementia. Interim findings from a multicentre study in general practice. Blakemore, C.B. Drugs (1987) [Pubmed]
  9. Cyclandelate versus flunarizine. A double-blind study in a selected group of patients with dementia. Albizzati, M.G., Bassi, S., Calloni, E., Sbacchi, M., Piolti, R., Frattola, L. Drugs (1987) [Pubmed]
  10. Effect of food on the bioavailability of cyclandelate from commercial capsules. Kaniwa, N., Ogata, H., Aoyagi, N., Ejima, A., Takahashi, T., Uezono, Y., Imazato, Y. Clin. Pharmacol. Ther. (1991) [Pubmed]
  11. Cyclandelate. An inhibitor of cholesterol esterification. Middleton, B., Cacciaguerra, F., White, D. Drugs (1987) [Pubmed]
  12. The influence of cyclandelate on Ca++ translocation in human platelets. Akkerman, J.W., van den Hoven, W.E. Drugs (1987) [Pubmed]
  13. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. The Study group. Diener, H.C., Föh, M., Iaccarino, C., Wessely, P., Isler, H., Strenge, H., Fischer, M., Wedekind, W., Taneri, Z. Cephalalgia : an international journal of headache. (1996) [Pubmed]
  14. Antimigraine drugs. Diener, H.C., Kaube, H., Limmroth, V. J. Neurol. (1999) [Pubmed]
  15. Influence of hypercapnia on the cerebrovascular activities of some drugs used in the treatment of cerebral ischemia. Cosnier, D., Cheucle, M., Rispat, G., Streichenberger, G. Arzneimittel-Forschung. (1977) [Pubmed]
  16. Influence of cyclandelate on in vitro red blood cell deformability. Hall, D.W., van den Hoven, W.E. Drugs (1987) [Pubmed]
  17. In vivo inhibition of hepatic lipogenesis in the rat by cyclandelate (3,3',5-trimethylcyclohexanylmandelate). Middleton, A., White, D.A., Bell, G.D., Middleton, B. Biochem. Pharmacol. (1983) [Pubmed]
  18. Effect of cyclandelate on prostacyclin release and cytosolic free calcium concentrations in human endothelial cells. van Hinsbergh, V.W. Drugs (1987) [Pubmed]
  19. Inhibition of human platelet functions by cyclandelate. van den Hoven, W.E., Hall, D.W. Drugs (1987) [Pubmed]
  20. Simultaneous determination of cyclandelate and its metabolite in human plasma by capillary column gas-liquid chromatography. Andermann, G., Dietz, M. J. Chromatogr. (1981) [Pubmed]
  21. Chemical synthesis of dual-radiolabelled cyclandelate and its metabolism in rat hepatocytes and mouse J774 cells. White, D.A., Heffron, F., Miciak, A., Middleton, B., Knights, S., Knight, D. Xenobiotica (1990) [Pubmed]
  22. Determination of plasma concentrations of cyclandelate and mandelic acid in patients with generalized atherosclerotic vasculopathy treated with oral cyclandelate. Forconi, S., Cappelli, R., Guerrini, M., Volpi, L., Frigerio, C., Di Perri, T. J. Int. Med. Res. (1990) [Pubmed]
  23. The inhibition of cholesterol esterification by cyclandelate in transformed mouse macrophages. Heffron, F., Middleton, B., White, D.A. Biochem. Pharmacol. (1993) [Pubmed]
  24. The effects of two acylcoenzyme A: cholesterol acyltransferase (ACAT) inhibitors, cyclandelate and a non-hydrolysable ether analogue, benzyl3,3,5-trimethylcyclohexanol on low density lipoprotein metabolism in macrophages and hepatocytes. White, D.A., Heffron, F., Knight, D., Salter, A.M. Biochem. Pharmacol. (1994) [Pubmed]
  25. Heterogeneity of biochemical actions among vasodilators. Greenslade, F.C., Scott, C.K., Newquist, K.L., Krider, K.M., Chasin, M. Journal of pharmaceutical sciences. (1982) [Pubmed]
  26. Pathophysiology and psychopharmacology of dementia--a new study design. 2. Cyclandelate treatment--a placebo-controlled double-blind clinical trial. Schellenberg, R., Todorova, A., Wedekind, W., Schober, F., Dimpfel, W. Neuropsychobiology (1997) [Pubmed]
  27. Efficacy and tolerance of cyclandelate versus pizotifen in the prophylaxis of migraine. Mastrosimone, F., Iaccarino, C., de Caterina, G. Journal of medicine. (1992) [Pubmed]
  28. Cyclandelate in the treatment of cerebral arteriosclerosis. Hall, P. Journal of the American Geriatrics Society. (1976) [Pubmed]
  29. Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study. Siniatchkin, M., Gerber, W.D., Vein, A. Funct. Neurol. (1998) [Pubmed]
  30. The anti-hypoxaemic effect of cyclandelate in man measured in human volunteers using computer-assisted oculodynamic methodology. Schaffler, K. British journal of clinical practice. Supplement. (1984) [Pubmed]
WikiGenes - Universities